Altered muscle metaboreflex control of coronary blood flow and ventricular function in heart failure

Eric J Ansorge1, Robert A Augustyniak, Mariana L Perinot

  • 1Department of Physiology, Wayne State University School of Medicine, Detroit, Michigan 48201, USA.

Insights

Muscle metaboreflex activation during heart failure (HF) impairs coronary blood flow and left ventricular performance. In HF, increased sympathetic tone constricts coronary vessels, limiting myocardial function during exercise.

Area of Science:

  • Cardiovascular Physiology
  • Exercise Physiology
  • Heart Failure Pathophysiology

Background:

  • The muscle metaboreflex is a neurocirculatory reflex activated by metabolic byproducts of muscle contraction.
  • Understanding its impact on coronary circulation and cardiac function is crucial, especially in conditions like heart failure (HF).

Purpose of the Study:

  • To investigate the effects of muscle metaboreflex activation on coronary blood flow (CBF), coronary vascular conductance (CVC), and left ventricular performance.
  • To compare these effects in healthy dogs versus dogs with induced heart failure (HF) during treadmill exercise.

Main Methods:

  • Conscious, instrumented dogs were subjected to treadmill exercise.
  • Muscle metaboreflex was activated during mild and moderate exercise.
  • Measurements included mean arterial pressure, heart rate, cardiac output, CBF, CVC, and myocardial shortening/relaxation rates.
  • Experiments were conducted before and after induction of HF.

Main Results:

  • In healthy dogs, metaboreflex activation increased cardiac output, CBF, and heart rate, without altering CVC or significantly impacting myocardial shortening/relaxation.
  • In dogs with HF, metaboreflex activation attenuated increases in mean arterial pressure and CBF, and significantly reduced CVC.
  • In HF, metaboreflex activation did not improve myocardial performance metrics during exercise.

Conclusions:

  • Muscle metaboreflex activation in the context of heart failure leads to impaired coronary vascular conductance and attenuated increases in coronary blood flow.
  • Elevated sympathetic tone during HF, triggered by the muscle metaboreflex, causes coronary vasoconstriction, potentially limiting myocardial performance during exercise.

Related Concept Videos

Pathophysiology of Cardiac Performance01:29

Pathophysiology of Cardiac Performance

Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...